Reisensburg Symposium

AML Intergroup

February 15, 2013

Organizer: Prof. Dr. Thomas Büchner

Summary

The AML Intergroup is part of the ELN and a structure of cooperation within different AML study groups in Europe. As a pilot project a network between 5 multicenter study groups in Germany has been created. This year's symposium has been dedicated to novel approaches in more successfully characterizing and treating human AML.

Scientific content of and discussion at the Symposium

Herve Dombret (Paris) was invited to discuss a European standard treatment potentially as a common standard arm. After developing a web based scoring system for older AML patients Utz Krug described a new AML Intergroup Study for predicting long term outcome in AML.. A different prognostic model is solely based upon molecular aberrations (Vera Großmann). Patient age has emerged as a leading independent risk factor whereas treatment intensity failed to predict outcome in the AMLCG 99 trial (Thomas Büchner). The novel methodology and data about next generation sequencing has been discussed in the context of ALL (Giovanni Martinelli, Bologna) and for MRD assessment in AML by Michael Heuser. Specific treatment targeted to risk groups has been explained by Christoph Röllig, targeted to FLT3-ITD by Sabine Kayser and targeted to biallelic CEBPA mutations by Richard Schlenk. The role of epigenetics and in particular DNA methyltransferase in AML has been addressed by Carsten Müller-Tidow. Allogeneic stem cell transplantation as the most important therapeutic alternative in AML has been evaluated by Matthias Stelljes using a prospective matched pair analysis.

Assessment of results and impact of the Symposium on the future direction of the field

Generally all data presented were unpublished and the meeting stimulated new cooperations mainly in Gemany but with some European perspectives.

Final Program

15:00 Plenary Session

Prediction of Time-Dependent Outcome Variables in Acute Myeloid Leukemia – an AML Intergroup Study	Utz Krug
Risk Adapted and Targeted Therapy for AML; Concepts and Results of the Study Alliance Leukemia SAL	Christoph Röllig
AlloSCT versus Conventional Post-Remission Therapy for AML in 1st CR, a Prospective Matched Pairs Analysis	Matthias Stelljes
DNA-Methyltransferase in AML	Carsten Müller-Tidow
A Novel Molecular Prognostic Model to Stratify AML	Vera Großmann
Adjusting for Risk Factors When Comparing Treatment Groups	Markus Pfirrmann
Next Generation Sequencing for MRD Assessment in Acute Myeloid Leukemia	Michael Heuser
Treatment of AML with Biallelic CEBPA Mutations, A Cooperative Group Meta-Analysis	Richard Schlenk
Concept and First Data of the AMLSG 16-10 trial with Midostaurin in AML with FLT3-ITD	Sabine Kayser
The Age Factor in AML	Thomas Büchner

18:30 Key Note Lectures

AML: Time for European Standard Therapy?	Hervé Dombret
Next Generation Sequencing, Potential Role in Acute Lymphoblastic Leukemia	Giovanni Martinelli

20:00 Dinner